ARA-290 (Cibinetide)

ARA-290 Research Peptide (Cibinetide / Non-Erythropoietic EPO Helix B Peptide)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses

ARA-290 (Cibinetide, PHBSP — Pyroglutamate Helix B Surface Peptide, CAS 1208243-50-8) is a synthetic 11 amino acid non-erythropoietic peptide derived from the helix B surface domain of erythropoietin (EPO), developed by Dr. Michael Brines and colleagues at Araim Pharmaceuticals to selectively activate the innate repair receptor (IRR) without engaging the classical erythropoietic EPOR homodimer, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. The IRR is a heterodimeric complex of the EPO receptor (EPOR) and the beta-common receptor (CD131, βCR) that is selectively upregulated in injured and inflamed tissue while largely absent in healthy uninjured cells. ARA-290 has received FDA Orphan Drug designation for sarcoidosis-associated neuropathy and has progressed through Phase 2 human clinical trials. For scientific research use only.

Compound Specifications

Why Research Laboratories Select ARA-290

ARA-290 is the primary research tool for investigating the innate repair receptor (IRR) — a tissue-injury-responsive EPOR/CD131 heterodimer that is mechanistically distinct from the classical EPOR homodimer responsible for erythropoiesis. Its deliberate engineering to eliminate all erythropoietic activity while retaining IRR agonism makes it an irreplaceable tool for dissecting the tissue-protective and anti-inflammatory dimensions of the EPO signaling system from the hematopoietic dimensions — a separation not possible with native EPO or non-selective EPO analogs.

• First selective IRR agonist — EPOR/CD131 heterodimer agonism without EPOR homodimer erythropoietic activation
• Injury-selective receptor activation — IRR is upregulated in injured/inflamed tissue, largely absent in healthy cells
• NF-κB inhibition — studied for suppression of pro-inflammatory cytokine cascades in cellular research models
• TRPV1 antagonism — studied for analgesic pathway modulation in nociceptive signaling research models
• Small fiber neuropathy research — Brines et al. published corneal nerve fiber density recovery data in Phase 2 clinical trials
• FDA Orphan Drug designation for sarcoidosis-associated neuropathy — Phase 2 clinical trial data available
• Islet protection research — Yao et al. (2021) published human islet transplantation protection data in Cell Transplantation
• Lyophilized format ensures stability and reproducibility across experimental runs

Research Background

ARA-290 was developed by Dr. Michael Brines at Araim Pharmaceuticals following the discovery that EPO signals through two distinct receptor complexes — an EPOR homodimer mediating erythropoiesis, and an EPOR/CD131 heterodimer (IRR) mediating tissue protection. Brines et al. characterized the helix B surface domain of EPO as responsible for IRR engagement. Phase 2 clinical trials were conducted in sarcoidosis-associated small fiber neuropathy — Drent et al. and Culver et al. published findings demonstrating increased corneal nerve fiber density and reduced neuropathic pain scores. FDA granted Orphan Drug designation for this indication. ARA-290 is not FDA approved for any indication. Research-grade ARA-290 supplied by Nextday Peptides is not equivalent to any investigational drug formulation. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.

Reference sources: Culver et al. (2014) — Molecular Medicine (Phase 2 sarcoidosis neuropathy) | Wikipedia — Cibinetide

Shipping & Fulfillment

• Ships from U.S. warehouses — Florida, North Carolina, and California
• Overnight and 2-day shipping available at checkout
• Same-day processing on orders placed before 3:30 PM ET
• Discreet packaging with full tracking provided
• Bulk research orders welcome — contact us for volume pricing

Storage & Handling

• Store lyophilized peptide at -20°C away from light and moisture
• After reconstitution store at 2–8°C and use within 14 days
• Aliquot into single-use portions to avoid repeated freeze-thaw cycles
• Handle using appropriate laboratory safety protocols
• Keep containers sealed when not in use

Frequently Asked Questions

For Research Use Only — Not for human or veterinary consumption • Not FDA approved for any indication • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only